| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Pathology, Radiotherapy and Medical Oncology, and Gynecology and Obstetrics, Kuopio Cancer Research Centre, University of Kuopio; and the A. I. Virtanen Institute, Kuopio, Finland
Abstract
The newly introduced Bethesda System proposes to replace the terms dysplasia, carcinoma in situ (CIS), or cervical intraepithelial neoplasia (CIN) with two terms, low-grade squamous intraepithelial lesion (SID or high-grade SIL. We tested the biologic relevance of the Bethesda System (ie, its ability to establish a close correlation between biologic behavior and the different grades of lesions) in a series of 528 women with genital human papillomavirus (HPV)- associated precancerous lesions prospectively followed for 10 years. The cervical biopsies were reclassified as either low-grade or high-grade SIL, and the data obtained by colposcopy, Papanicolaou smear, and HPV typing, as well as the biological behavior of the lesions, were analyzed in these two groups. Altogether, 77.4% (376 of 486) of the lesions were classified as low-grade SIL lesions; the rest (22.6%) belonged to the high-grade SIL category. In the low-grade SIL category, 46.8% of the women were 24 years old or younger, as compared with 37.3% in the high-grade SIL group. The colposcopic appearance was normal significantly more frequently in the low-grade SIL lesions (22.1%) than in the high-grade category (8.5%) (P < 001). A single Fapanicolaou smear was inadequate to distinguish between low-grade and high-grade SIL, as evidenced by almost identical distributions of Papanicolaou smear class I and II cells in both categories. Noteworthy was the discovery of normal Papanicolaou smears in 8.2% of the high-grade SIL lesions. Four of the HPV types analyzed (6,11,18, 33) were similarly distributed in both categories, whereas HPVs 16 and 31 were significantly more frequent in high-grade as compared with low-grade SIL (P <.001). The spontaneous regression rate was significantly higher in low-grade SIL (63.6%) than in high-grade SIL (38.2%). Progression was significantly higher (39.1%) in the high-grade SIL category (P<.0001). Despite its definitely positive goals, the drawbacks of the Bethesda System still outnumber its advantages. Most important, simplification of the classification into two grades instead of three in the CIN terminology inevitably leads to significant loss of diagnostically and prognostically valuable information. From the patient's point of view, it is essential that clinical terminology does not result in overtreatment, which seems to be a definite risk using only the two categories of the Bethesda System. The present results firmly advocate preservation of the current descriptive terminology, which has proven its effectiveness for many years.
This article has been cited by other articles:
|
|
 |
|
  M.-Y. Lee, C.-Y. Chou, M.-J. Tang, and M.-R. Shen Epithelial-Mesenchymal Transition in Cervical Cancer: Correlation with Tumor Progression, Epidermal Growth Factor Receptor Overexpression, and Snail Up-Regulation Clin. Cancer Res., August 1, 2008; 14(15): 4743 - 4750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kim, K. M. Kuntz, N. K. Stout, S. Mahmud, L. L. Villa, E. L. Franco, and S. J. Goldie Multiparameter Calibration of a Natural History Model of Cervical Cancer Am. J. Epidemiol., July 15, 2007; 166(2): 137 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Shen, Y.-M. Hsu, K.-F. Hsu, Y.-F. Chen, M.-J. Tang, and C.-Y. Chou Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by {alpha}v{beta}3 integrin signaling Carcinogenesis, May 1, 2006; 27(5): 962 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Siebert, G. Sroczynski, P. Hillemanns, J. Engel, R. Stabenow, C. Stegmaier, K. Voigt, B. Gibis, D. Holzel, and S. J. Goldie The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany Eur J Public Health, April 1, 2006; 16(2): 185 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kim, T. C. Wright, and S. J. Goldie Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy J Natl Cancer Inst, June 15, 2005; 97(12): 888 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, M. Kohli, D. Grima, M. C. Weinstein, T. C. Wright, F. X. Bosch, and E. Franco Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine J Natl Cancer Inst, April 21, 2004; 96(8): 604 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Goldie, J. J. Kim, and T. C. Wright Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More Obstet. Gynecol., April 1, 2004; 103(4): 619 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Sawaya, K. J. McConnell, S. L. Kulasingam, H. W. Lawson, K. Kerlikowske, J. Melnikow, N. C. Lee, G. Gildengorin, E. R. Myers, and A. E. Washington Risk of Cervical Cancer Associated with Extending the Interval between Cervical-Cancer Screenings N. Engl. J. Med., October 16, 2003; 349(16): 1501 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Shen, C.-Y. Chou, K.-F. Hsu, Y.-M. Hsu, W.-T. Chiu, M.-J. Tang, S. L. Alper, and J. C. Ellory KCl Cotransport Is an Important Modulator of Human Cervical Cancer Growth and Invasion J. Biol. Chem., October 10, 2003; 278(41): 39941 - 39950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saslow, C. D. Runowicz, D. Solomon, A.-B. Moscicki, R. A. Smith, H. J. Eyre, and C. Cohen American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer CA Cancer J Clin, November 1, 2002; 52(6): 342 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kim, T. C. Wright, and S. J. Goldie Cost-effectiveness of Alternative Triage Strategies for Atypical Squamous Cells of Undetermined Significance JAMA, May 8, 2002; 287(18): 2382 - 2390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Herbst, K. E. Pickett, M. Follen, and K. L. Noller The Management of ASCUS Cervical Cytologic Abnormalities and HPV Testing: A Cautionary Note Obstet. Gynecol., November 1, 2001; 98(5): 849 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, L. Kuhn, L. Denny, A. Pollack, and T. C. Wright Policy Analysis of Cervical Cancer Screening Strategies in Low-Resource Settings: Clinical Benefits and Cost-effectiveness JAMA, June 27, 2001; 285(24): 3107 - 3115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-B. Moscicki, N. Hills, S. Shiboski, K. Powell, N. Jay, E. Hanson, S. Miller, L. Clayton, S. Farhat, J. Broering, et al. Risks for Incident Human Papillomavirus Infection and Low-Grade Squamous Intraepithelial Lesion Development in Young Females JAMA, June 20, 2001; 285(23): 2995 - 3002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holowaty, A. B. Miller, T. Rohan, and T. To Natural History of Dysplasia of the Uterine Cervix J Natl Cancer Inst, February 3, 1999; 91(3): 252 - 258. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
